Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

Author(s):: Baron, F.; Stevens-Kroef, M.; Kicinski, M.; Meloni, G.; Muus, P.; Marie, J.P.; Halkes, C.J.M.; Thomas, X.; Vrhovac, R.; Specchia, G.; Lefrere, F.; Sica, S.; Mancini, M.; Venditti, A.; Hagemeijer, A.; Becker, H.; Jansen, J.H.; Amadori, S.; Witte, T. de; Willemze, R.; Suciu, S.

Published: 2018
Publication type: Article / Letter to editor

AMLCytogeneticClonal heterogeneityClonal evolutionTransplantation

Date issued: 2018-10-31
Language: English
Is part of: Annals of Hematology (2018), Vol. 97, no. 10, p. 1785-1795
hdl: 1887/86523
doi: 10.1007/s00277-018-3396-4